InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Hurvitz Chaim, Director. Officer active across 1 company, notably NRX Pharmaceuticals, Inc.. In total, 5 reports have been recorded. Split: 3 buys · 0 sell. Total volume traded: €569k. Activity tracked since 16 November 2022. The latest transaction was disclosed on 30 August 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations5 total
70,000 shares@ US$0.28753.2% of flowCommon Stock, par value $0.001 per shareSEC:0001415889-23-013137:0
Ideal exit: 26 May 2024 (T+270)
287,812 shares@ US$0.9948.4% of flowCommon StockSEC:0000950142-22-003250:0
Ideal exit: 13 Aug 2023 (T+270)
287,812 shares@ US$0.9948.4% of flowCommon StockSEC:0000950142-22-003233:0
Ideal exit: 13 Aug 2023 (T+270)
1,436,350 sharesCommon StockSEC:0000950142-21-001942
1,436,350 sharesCommon StockSEC:0000950142-21-001942:0
5 of 5 declarations
About Hurvitz Chaim
Chaim Hurvitz is a Director at NRX Pharmaceuticals, Inc. As a board member, he contributes to the governance of the company and strategic decision-making. His experience in the pharmaceutical sector allows him to make significant contributions to discussions on the company's direction. He is committed to supporting growth and innovation within NRX Pharmaceuticals.
